MDRX - Veradigm gains on announcing new share repurchase program initiates fiscal 2023 guidance

January, 11 2023 09:05 AM Allscripts Healthcare Solutions Inc.

Veradigm ( NASDAQ: MDRX ) formerly Allscripts Healthcare Solutions, initiates financial guidance for fiscal 2023 and approves a new share repurchase program to purchase up to $250M of its common stock.
The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250M of common stock which was almost fully utilized during 2022.
In 4Q22 the company repurchased $57M of its common stock, bringing its full year total to $234M.
Additionally, the company expects FY23 revenue between $640M and $660M vs consensus of $656.51M , non-GAAP earnings per share is expected between $0.90 and $1.00 vs consensus of $0.89 .
Shares are trading up 2.47% premarket.

For further details see:

Company Name:	Allscripts Healthcare Solutions Inc.
Stock Symbol:	MDRX
Market:	NASDAQ
Website:	allscripts.com